Antihyperglycemic effect of ganoderma lucidum polysaccharides on streptozotocin-induced diabetic mice

Abstract

The current study evaluated the glucose-lowering effect of ganoderma lucidum polysaccharides (Gl-PS) in streptozotocin (STZ)-induced diabetic mice. The diabetic mice were randomly divided into four groups (8 mice per group): diabetic control group, low-dose Gl-PS treated group (50 mg/kg, Gl-PS), high-dose Gl-PS treated group (150 mg/kg, Gl-PS) and positive drug control treated group (glibenclamide, 4 mg/kg), with normal mice used as the control group. Body weights, fasting blood glucose (FBG), serum insulin and blood lipid levels of mice were measured. After 28 days of treatment with Gl-PS, body weights and serum insulin levels of the Gl-PS treated groups was significantly higher than that of the diabetic control group, whereas FBG levels was significantly lower. Moreover, total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels of the Gl-PS treated groups had dropped, whereas the high density lipoprotein cholesterol (HDL-C) levels had increased. In addition, according to acute toxicity studies, Gl-PS did not cause behavioral changes and any death of mice. These data suggest that Gl-PS has an antihyperglycemic effect. Furthermore, considering the Gl-PS effects on lipid profile, it may be a potential hypolipidaemic agent, which will be a great advantage in treating diabetic conditions associated with atherosclerosis or hyperlipidemia.

Keywords: antihyperglycemic; diabetic mice; ganoderma lucidum polysaccharides; streptozotocin.

Figure 1

Effects of Gl-PS on body weights in mice. Data were presented as means ± SD. NC group: normal control group, DC group: diabetic control group, LGT group: low-dose Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control treated group. ^a P < 0.05 as compared with NC group. ^b P < 0.05 as compared with DC group.

Figure 2

Effects of Gl-PS on fasting blood glucose levels in mice. Data were presented as means ± SD. NC group: normal control group, DC group: diabetic control group, LGT group: low-dose Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control treated group. ^a P < 0.05 as compared with NC group. ^b P < 0.05 as compared with DC group.

Figure 3

Effects of Gl-PS on serum insulin levels in mice. Data were presented as means ± SD. NC group: normal control group, DC group: diabetic control group, LGT group: low-dose Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control treated group. ^a P < 0.05 as compared with NC group. ^b P < 0.05 as compared with DC group.

Figure 4

Effects of Gl-PS on blood lipid levels in mice. Data were presented as means ± SD. NC group: normal control group, DC group: diabetic control group, LGT group: low-dose Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control treated group. ^a P < 0.05 as compared with NC group. ^b P < 0.05 as compared with DC group.